Rob Freedman, Fenwick’s co-chair for capital markets and public companies, spoke to GeekWire about the unprecedented surge in biotech IPOs in Washington state this year.
Freedman spoke to the release about the strength of the biotech and healthcare market, especially since the pandemic began. During the recent boom, “investors are throwing a wider web” beyond the concentrated biotech hubs of San Francisco and Boston, he said. “You realize there’s more out there.”
Freedman noted that as the Pacific Northwest biotech scene continues to grow, proven leadership will help attract capital and marquee investors. “Good leaders, good investors: I think it’s kind of a snowball,” he said, adding, “We’ll see how long it takes.”
The full article is available on GeekWire.